DCTH Stock — Delcath Systems Inc

Delcath Systems Inc (DCTH)

Updated October 16, 2026.

DCTH is a Stock. Its deepest 1-year drawdown was 33.7%.

Delcath Systems is an interventional oncology company developing treatments for primary and metastatic liver cancers in the United States and Europe. Its lead product candidate is HEPZATO KIT, a chemotherapy delivery system designed to administer high-dose melphalan to the liver while limiting systemic side effects, currently in clinical trials for metastatic uveal melanoma; the company also markets a related device called CHEMOSAT for treating various liver cancers in European medical centers. The company does not currently distribute dividends.

DCTH performance

Returns are updating. DCTH's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 33.7%.

DCTH key facts

Asset type

Stock

Asset class

Equity

Inception date

10/23/2001

Distribution frequency

None

Last close

$14.08 (as of 2026-10-16)

Market cap

$488,559,034

Average volume

383853.0

Payment date

12/24/2019

Beta

0.597

Payout ratio

0.0%

P/E ratio

1408.0

Forward P/E

232.5581

EPS

$0.01

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DCTH risks and drawbacks

The deepest 1-year drawdown on record here is 33.7%.

Who may consider DCTH — and who may not

It is a weaker fit for investors who need monthly cash flow (DCTH does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on DCTH

• All tickers starting with D

Tagged: Healthcare.

Frequently asked questions